An adenovirus-vectored nasal vaccine confers rapid and sustained protection against anthrax in a single-dose regimen

Clinical and Vaccine Immunology

Volumn 20, Issue 1, 2013, Pages 1-8

  Zhang, Jianfeng ^a   Jex, Edward ^a,d   Feng, Tsungwei ^a   Sivko, Gloria S ^b   Baillie, Leslie W ^c,e   Goldman, Stanley ^c   Van Kampen, Kent R ^a   Tang, De Chu C ^a,f  

^a Vaxin Inc   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

^c NAVAL MEDICAL RESEARCH CENTER   (United States)

^d SOUTHERN RESEARCH INSTITUTE   (United States)

^e CARDIFF UNIVERSITY   (United Kingdom)

^f not available   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTHRAX VACCINE; BACTERIAL ANTIGEN; BACTERIAL RNA; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; LETHAL GENE IMMUNOGLOBULIN A ANTIBODY; LETHAL GENE IMMUNOGLOBULIN G ANTIBODY; LETHAL TOXIN NEUTRALIZING ANTIBODY; NEUTRALIZING ANTIBODY; PROTECTIVE ANTIGEN; PROTECTIVE ANTIGEN IMMUNOGLOBULIN A ANTIBODY; PROTECTIVE ANTIGEN IMMUNOGLOBULIN G ANTIBODY; TRANSFER RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL GENE; BACTERIAL IMMUNITY; CODON; CONTROLLED STUDY; DRUG MEGADOSE; DRUG POTENCY; FEMALE; GENE POOL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; INFECTION PREVENTION; LETHAL GENE; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; VIRUS IMMUNITY;

EID: 84872231747     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00280-12     Document Type: Article

References (45)

1. Baillie LW. 2009. Is new always better than old?: the development of human vaccines for anthrax. Hum. Vaccin. 5:806-812.
2. Inglesby TV, O'Toole T, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Friedlander AM, Gerberding J, Hauer J, Hughes J, McDade J, Osterholm MT, Parker G, Perl TM, Russell PK, Tonat K, Working Group on Civilian Biodefense. 2002. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 287:2236-2252.
3. Green BD, Battisti L, Koehler TM, Thorne CB, Ivins BE. 1985. Demonstration of a capsule plasmid in Bacillus anthracis. Infect. Immun. 49:291-297.
4. Moayeri M, Leppla SH. 2009. Cellular and systemic effects of anthrax lethal toxin and edema toxin. Mol. Aspects Med. 30:439-455.
5. Friedlander AM, Welkos SL, Pitt ML, Ezzell JW, Worsham PL, Rose KJ, Ivins BE, Lowe JR, Howe GB, Mikesell P, Lawrence WB. 1993. Postexposure prophylaxis against experimental inhalation anthrax. J. Infect. Dis. 167:1239-1243.
6. Henderson DW, Peacock S, Belton FC. 1956. Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J. Hyg. (Lond.) 54:28-36.
7. Little S. 2005. Anthrax vaccines: a development update. BioDrugs 19:233-245.
8. Wright JG, Quinn CP, Shadomy S, Messonnier N, Centers for Disease Control and Prevention. 2010. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm. Rep. 59:1-30.
9. Fellows PF, Linscott MK, Ivins BE, Pitt ML, Rossi CA, Gibbs PH, Friedlander AM. 2001. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 19:3241-3247.
10. Langley WA, Bradley KC, Li ZN, Smith ME, Schnell MJ, Steinhauer DA. 2010. Induction of neutralizing antibody responses to anthrax protective antigen by using influenza virus vectors: implications for disparate immune system priming pathways. J. Virol. 84:8300-8307.
11. McConnell MJ, Hanna PC, Imperiale MJ. 2007. Adenovirus-based prime-boost immunization for rapid vaccination against anthrax. Mol. Ther. 15:203-210.
12. Santra S, Seaman MS, Xu L, Barouch DH, Lord CI, Lifton MA, Gorgone DA, Beaudry KR, Svehla K, Welcher B, Chakrabarti BK, Huang Y, Yang ZY, Mascola JR, Nabel GJ, Letvin NL. 2005. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J. Virol. 79:6512-6522.
13. Shi Z, Zeng M, Yang G, Siegel F, Cain LJ, van Kampen KR, Elmets CA, Tang DC. 2001. Protection against tetanus by needle-free inoculation of adenovirus-vectored nasal and epicutaneous vaccines. J. Virol. 75:11474-11482.
14. Van Kampen KR, Shi Z, Gao P, Zhang J, Foster KW, Chen DT, Marks D, Elmets CA, Tang DC. 2005. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 23:1029-1036.
15. Arora N, Klimpel KR, Singh Y, Leppla SH. 1992. Fusions of anthrax toxin lethal factor to the ADP-ribosylation domain of Pseudomonas exotoxin A are potent cytotoxins which are translocated to the cytosol of mammalian cells. J. Biol. Chem. 267:15542-15548.
16. Klimpel KR, Arora N, Leppla SH. 1994. Anthrax toxin lethal factor contains a zinc metalloprotease consensus sequence which is required for lethal toxin activity. Mol. Microbiol. 13:1093-1100.
17. Fallaux FJ, Bout A, van der Velde I, van den Wollenberg DJ, Hehir KM, Keegan J, Auger C, Cramer SJ, van Ormondt H, van der Eb AJ, Valerio D, Hoeben RC. 1998. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum. Gene Ther. 9:1909-1917.
18. Tang DC, Zhang J, Toro H, Shi Z, Van Kampen KR. 2009. Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines. Expert Rev. Vaccines 8:469-481.
19. Evans RK, Nawrocki DK, Isopi LA, Williams DM, Casimiro DR, Chin S, Chen M, Zhu DM, Shiver JW, Volkin DB. 2004. Development of stable liquid formulations for adenovirus-based vaccines. J. Pharm. Sci. 93:2458-2475.
20. Zhang J, Shi Z, Kong FK, Jex E, Huang Z, Watt JM, Van Kampen KR, Tang DC. 2006. Topical application of Escherichia coli-vectored vaccine as a simple method for eliciting protective immunity. 2006. Topical application of Escherichia coli-vectored vaccine as a simple method for eliciting protective immunity. Infect Immun. 174:3607-3617.
21. Price BM, Liner AL, Park S, Leppla SH, Mateczun A, Galloway DR. 2001. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect. Immun. 69:4509-4515.
22. Berdichevsky M, Gentile MP, Hughes B, Meis P, Peltier J, Blumentals I, Auniņs J, Altaras NE. 2008. Establishment of higher passage PER.C6 cells for adenovirus manufacture. Biotechnol. Prog. 24:158-165.
23. Croyle MA, Cheng X, Wilson JM. 2001. Development of formulations that enhance physical stability of viral vectors for gene therapy. Gene Ther. 8:1281-1290.
24. Alcock R, Cottingham MG, Rollier CS, Furze J, De Costa SD, Hanlon M, Spencer AJ, Honeycutt JD, Wyllie DH, Gilbert SC, Bregu M, Hill AV. 2010. Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass. Sci. Transl. Med. 2:19ra12.
25. Fernández E, Toledo JR, Chiong M, Parra F, Rodríguez E, Montero C, Méndez L, Capucci L, Farnós O. 2011. Single dose adenovirus vectored vaccine induces a potent and long-lasting immune response against rabbit hemorrhagic disease virus after parenteral or mucosal administration. Vet. Immunol. Immunopathol. 142:179-188.
26. + T-cell-independent immunity from adenovirus-encoded vaccine antigens. J. Gen. Virol. 88:1708-1716.
27. Hu RL, Liu Y, Zhang SF, Zhang F, Fooks AR. 2007. Experimental immunization of cats with a recombinant rabies-canine adenovirus vaccine elicits a long-lasting neutralizing antibody response against rabies. Vaccine 25:5301-5307.
28. Tan Y, Hackett NR, Boyer JL, Crystal RG. 2003. Protective immunity evoked against anthrax lethal toxin after a single intramuscular administration of an adenovirus-based vaccine encoding humanized protective antigen. Hum. Gene Ther. 14:1673-1682.
29. Cleret A, Quesnel-Hellmann A, Vallon-Eberhard A, Verrier B, Jung S, Vidal D, Mathieu J, Tournier JN. 2007. Lung dendritic cells rapidly mediate anthrax spore entry through the pulmonary route. J. Immunol. 178:7994-8001.
30. Glomski IJ, Piris-Gimenez A, Huerre M, Mock M, Goossens PL. 2007. Primary involvement of pharynx and Peyer's patch in inhalational and intestinal anthrax. PLoS Pathog. 3:e76. doi:10.1371/journal.ppat.0030076.
31. Russell BH, Vasan R, Keene DR, Koehler TM, Xu Y. 2008. Potential dissemination of Bacillus anthracis utilizing human lung epithelial cells. Cell Microbiol. 10:945-957.
32. Flick-Smith HC, Eyles JE, Hebdon R, Waters EL, Beedham RJ, Stagg TJ, Miller J, Alpar HO, Baillie LW, Williamson ED. 2002. Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice. Infect. Immun. 70:2022-2028.
33. Huang J, Mikszta JA, Ferriter MS, Jiang G, Harvey NG, Dyas B, Roy CJ, Ulrich RG, Sullivan VJ. 2007. Intranasal administration of dry powder anthrax vaccine provides protection against lethal aerosol spore challenge. Hum. Vaccin. 3:90-93.
34. Mikszta JA, Sullivan VJ, Dean C, Waterston AM, Alarcon JB, JPDekker 3rd, Brittingham JM, Huang J, Hwang CR, Ferriter M, Jiang G, Mar K, Saikh KU, Stiles BG, Roy CJ, Ulrich RG, Harvey NG. 2005. Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms. J. Infect. Dis. 191:278-288.
35. Lemiale F, Kong WP, Akyürek LM, Ling X, Huang Y, Chakrabarti BK, Eckhaus M, Nabel GJ. 2003. Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J. Virol. 77:10078-10087.
36. Wang J, Thorson L, Stokes RW, Santosuosso M, Huygen K, Zganiacz A, Hitt M, Xing Z. 2004. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J. Immunol. 173:6357-6365.
37. Molinier-Frenkel V, Lengagne R, Gaden F, Hong SS, Choppin J, Gahery-Ségard H, Boulanger P, Guillet JG. 2002. Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response. J. Virol. 76:127-135.
38. Jones FR, Gabitzsch ES, Xu Y, Balint JP, Borisevich V, Smith J, Smith J, Peng BH, Walker A, Salazar M, Paessler S. 2011. Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine. Vaccine 29:7020-7026.
39. Patel A, Zhang Y, Croyle M, Tran K, Gray M, Strong J, Feldmann H, Wilson JM, Kobinger GP. 2007. Mucosal delivery of adenovirus-based vaccine protects against Ebola virus infection in mice. J. Infect. Dis. 2:S413-420.
40. Croyle MA, Patel A, Tran KN, Gray M, Zhang Y, Strong JE, Feldmann H, Kobinger GP. 2008. Nasal delivery of an adenovirus-based vaccine bypasses preexisting immunity to the vaccine carrier and improves the immune response in mice. PLoS One 3: e3548. doi:10.1371/journal.pone.0003548.
41. Xu Q, Pichichero ME, Simpson LL, Elias M, Smith LA, Zeng M. 2009. An adenoviral vector-based mucosal vaccine is effective in protection against botulism. Gene Ther. 16:367-375.
42. Yu JR, Kim S, Lee JB, Chang J. 2008. Single intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infection. J. Virol. 82:2350-2357.
43. Rhie GE, Roehrl MH, Mourez M, Collier RJ, Mekalanos JJ, Wang JY. 2003. A dually active anthrax vaccine that confers protection against both bacilli and toxins. Proc. Natl. Acad. Sci. U. S. A. 100:10925-10930.
44. Hahn UK, Boehm R, Beyer W. 2006. DNA vaccination against anthrax in mice-combination of anti-spore and anti-toxin components. Vaccine 24:4569-4571.
45. Hermanson G, Whitlow V, Parker S, Tonsky K, Rusalov D, Ferrari M, Lalor P, Komai M, Mere R, Bell M, Brenneman K, Mateczun A, Evans T, Kaslow D, Galloway D, Hobart P. 2004. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proc. Natl. Acad. Sci. U. S. A. 101:13601-13606.